The firm aims to have its test on the European clinical market by early next year, followed by a launch in the US.
The firm has licensed its test to Abbott, BioMérieux, and Quanterix, and it is working with the US Department of Defense as part of a collaborative approach.
Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.
Guardant Health said that its Guardant360 liquid biopsy assay has received expedited access pathway designation from the US Food and Drug Administration.
The test from Banyan Biomarkers called the Brain Trauma Indicator measures the levels of the proteins UCH-L1 and GFAP that are released into the blood.
Alere received FDA 510(k) clearances for four tests, including those for influenza A and B, strep A, and RNA-based respiratory syncytial virus.
Angle aims to show that clinicians can determine HER-2 status by subjecting harvested circulating tumor cells to fluorescence in situ hybridization (FISH).
Abbott's CEO said it is going to take a couple of years to get product launches and revenue growth that the company wants to see from its acquisition of Alere.
Abbott's CFO said he expects mid-single-digit growth from diagnostics in Q1 2018 and mid-to-high single digit growth for the full year.
The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.